{"id":"fimasartan-or-fimasartan-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Cough"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fimasartan binds to and blocks the angiotensin II type 1 (AT1) receptor on vascular smooth muscle and other tissues, preventing angiotensin II-mediated vasoconstriction and aldosterone release. This leads to vasodilation and reduced sodium retention, resulting in decreased blood pressure. The hydrochlorothiazide combination formulation adds a thiazide diuretic mechanism to enhance antihypertensive efficacy.","oneSentence":"Fimasartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor to reduce vasoconstriction and lower blood pressure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:40.169Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Hypertension (combination therapy with hydrochlorothiazide)"}]},"trialDetails":[{"nctId":"NCT05413057","phase":"","title":"An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2022-06-23","conditions":"Hypertension,Essential","enrollment":20000},{"nctId":"NCT03246555","phase":"PHASE3","title":"Fimasartan in the Senior Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-07-15","conditions":"The Elderly (≥ 70 Years) With Essential Hypertension","enrollment":241},{"nctId":"NCT02466490","phase":"PHASE3","title":"Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Stendhal Americas, S.A.","startDate":"2013-04","conditions":"Hypertension, Essential","enrollment":272}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":137,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fimasartan or Fimasartan/Hydrochlorothiazide","genericName":"Fimasartan or Fimasartan/Hydrochlorothiazide","companyName":"Boryung Pharmaceutical Co., Ltd","companyId":"boryung-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fimasartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor to reduce vasoconstriction and lower blood pressure. Used for Hypertension, Hypertension (combination therapy with hydrochlorothiazide).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}